参考文献 [1]Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med 2018; 378:331-344 [2]Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma...
Half-life:ADC—4–6 days. Time/action profile (blood levels) ROUTEONSETPEAKDURATION IV (ADC)unkend of infusion3 wk IV (MMAE)unk1–3 days3 wk Contraindications/Precautions Contraindicated in:Concurrent use of bleomycin (↑ risk of pulmonary toxicity);Obstetric:PregnancyLactation:Breast feeding sho...
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression 整理:肿瘤资讯 来源:肿瘤资讯 抗CD30的抗体偶联药物(ADC)BV治疗间变大细胞淋巴瘤(ALCL)和霍奇金淋巴瘤...
外周T细胞淋巴瘤是一种异质性的罕见群体,表现为侵袭性淋巴增生性疾病,在全球约占非霍奇金淋巴瘤的10%~15%。在Ⅰ期临床试验中,A+CHP方案(brentuximab vedotin+环磷酰胺+多柔比星+泼尼松)在治疗CD30阳性外周T细胞淋巴瘤中显示出令人鼓舞的活性和可控的安全性。Ⅲ期ECHELON-2临床试验将比较A+CHP方案与CHOP方案(环磷...
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma. PMID: 28190142 Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. PMID: 34507350 Brentuximab vedotin. PMID: 22212672 ...
Brentuximab vedotin is highly active in relapsed HL and was recently approved with doxorubicin, vinblastine, and dacarbazine (AVD) for previously untreated stage III/IV HL. We evaluated brentuximab-AVD for nonbulky stage I/II HL in a multicenter phase 2 study. Patients received a lead-in cycle...
Brentuximab Vedotin. PMID: 31644109 Brentuximab vedotin in T-cell lymphoma. PMID: 30526166 Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. PMID: 33721562 ...
The ECHELON-2 Trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol, 2021 Dec 15; S0923-7534(21)04875-4. doi: 10.1016/j.a...
In Vitro:Brentuximab vedotin (cAC10-vcMMAE) (1 μg/mL; 96 h) shows cytotoxicity to CD30+in Karpas 299 cells. Brentuximab vedotin (CAC10-VCMMAE) (1 μg/mL; 12, 24 and 48 h) selectively induces growth arrest in G2/M phase then lead to apoptotic cell death. ...
BrentuximabvedotinavailabletoR/RHL/sALCLpatientsonNamedPatientProgram Were-evaluatedtheefficacyandsafetyofNPPdatainapooledliteratureanalysis Overallresponserateswere67%inR/RHLand75%inR/RsALCL Completeremissionrateswere26%inR/RHLand74%inR/RsALCL ‘Real-world’safetywassimilartothatreportedinthepivotalphase2trials...